0001104659-22-055573 8-K 14 20220504 2.02 9.01 20220504 20220504 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 22889938 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2214339d1_8k.htm FORM 8-K
0001477845 false 0001477845 2022-05-04 2022-05-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): May 4, 2022





(Exact Name of Registrant as Specified in Charter) 


Delaware   001-39202   26-2540421

(State or Other Jurisdiction

of Incorporation)



File Number)


(I.R.S. Employer

Identification No.)


1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)


(610) 727-3913

Registrant’s Telephone Number, Including Area Code


                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x






Item 2.02 Results of Operations and Financial Condition.


On May 4, 2022, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.


The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits.


99.1  Press Release, dated May 4, 2022.
104  Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 4, 2022 By: /s/ Jeffrey McGroarty  
    Name: Jeffrey McGroarty
    Title: Chief Financial Officer




EX-99.1 2 tm2214339d1_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1



Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update


Berwyn, Pennsylvania – May 4, 2022 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.


Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, “we have made significant progress advancing buntanetap in Parkinson’s disease and Alzheimer’s disease this quarter. We received positive feedback from the U.S. Food and Drug Administration (FDA) for two Phase 3 clinical trials with buntanetap in early and late Parkinson’s disease. As our clinical trials advance, we have continued to build out our diverse team of highly motivated industry experts as we move to the next stage of clinical development.”


Recent Highlights and New Developments


·Clinical Advancement of buntanetap for PD: The Company held a successful Type B meeting with the FDA with regard to the Company's planned Phase 3 clinical studies of buntanetap for the treatment of Parkinson's Disease (PD). The FDA provided feedback on the initiation of the Phase 3 clinical studies of buntanetap for PD in parallel with the Alzheimer’s disease (AD) program. The agency detailed guidance on the specific endpoints, entry criteria, and further study parameters for two Phase 3 studies that would support a broad indication for both early and late PD.


·Announced Phase 3 Trial Design for PD: The Company announced the trial design of the upcoming Phase 3 trial evaluating buntanetap in early PD. The study is designed to enroll 450 PD patients with Hoehn & Yahr scale scores of 1, 2 and 3 and randomize them at 1:1:1 ratio into placebo, 10mg or 20mg buntanetap once daily on top of their standard of care for six months. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III will be used as primary endpoints, while total MDS-UPDRS and Participant Global Impression of Change will be secondary endpoints. In addition, Wechsler Adult Intelligence Scale, plasma biomarkers and Mini-Mental State Examination will be evaluated as exploratory endpoints.


·Expansion of the leadership team: The Company announced the appointment of Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations to advance the Company’s regulatory objectives. Eve joins Annovis with more than 35 years of experience in the biotechnology sector with a focus on the definition and execution of regulatory strategies. Additionally, the Company announced the promotion of Cheng Fang, Ph.D., to Senior Vice President of Research & Development to advance the Company’s clinical objectives. Cheng is an experienced neuroscientist with over a decade of experience studying neurodegenerative diseases.






·Receipt of USAN Assigned Name: The Company announced receipt of the United States Adopted Names Council assigned name "buntanetap" for the Company's lead drug candidate previously known as ANVS401/Posiphen.


Financial Results for the First quarter of 2022


Cash, cash equivalents, and marketable securities were $42.7 million as of March 31, 2022. Research and development expenses for the quarter ended March 31, 2022, were $2.8 million, compared to $2.4 million for the same period in 2021. The increase was primarily the result of an increase of $1.2 million in stock-based compensation expense, partially offset by a decrease of $0.7 million in expenses related to the Company’s two Phase 2a clinical trials which were completed in 2021. General and administrative expenses for the quarter ended March 31, 2022, were $3.1 million, compared to $0.8 million for the same period in 2021. The increase was primarily the result of increases of $2.2 million in stock-based compensation expense and $0.1 million in professional fees.


For the quarter ended March 31, 2022, Annovis reported a net loss of $5.9 million, compared to a net loss of $3.2 million for the same period in 2021.


About Annovis Bio, Inc.


Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and other chronic neurodegenerative diseases, including Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study buntanetap showed improvements in cognition and memory in AD as well as body and brain function in PD patients.


For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.







Forward-Looking Statements


Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.


Media and Investor Contact: 

Nic Johnson 

Russo Partners, LLC 

(303) 482-6405 





EX-101.SCH 3 anvs-20220504.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20220504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20220504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2214339d1_ex99-1img001.jpg GRAPHIC begin 644 tm2214339d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
May 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 04, 2022
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-3913
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2214339d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2022-05-04 2022-05-04 iso4217:USD shares iso4217:USD shares 0001477845 false 8-K 2022-05-04 ANNOVIS BIO, INC. DE 001-39202 26-2540421 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2214339d1_8k.htm anvs-20220504.xsd anvs-20220504_lab.xml anvs-20220504_pre.xml tm2214339d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2214339d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2214339d1_8k.htm" ] }, "labelLink": { "local": [ "anvs-20220504_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20220504_pre.xml" ] }, "schema": { "local": [ "anvs-20220504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20220504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2214339d1_8k.htm", "contextRef": "From2022-05-04to2022-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://annovisbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2214339d1_8k.htm", "contextRef": "From2022-05-04to2022-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-055573-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-055573-xbrl.zip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end